The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
In vitro effects of the novel JAK II inhibitor BSK805 in BCR-ABL and JAK II V617F-positive cell lines.
F. Ringel
No relevant relationships to disclose
J. Kaeda
No relevant relationships to disclose
M. Schwarz
No relevant relationships to disclose
B. Dörken
No relevant relationships to disclose
P. D. le Coutre
Honoraria - Novartis
Research Funding - Novartis